Newspatrolling.com News cum Content Syndication Portal Online
FY2025 Performance Highlights
- Revenue at ₹45,653m, grew 17.2% YoY
- Gross margin at ₹25,854m, grew 20.5% YoY
- EBITDA grew 36.8% YoY to ₹8,028m with EBITDA margin at 17.6%, grew 252bps YoY
- US revenue at $291m, grew 21.8% YoY
- Operational PAT at ₹3,447m, Grew 12x YoY
- Operational EPS at ₹37.5, Grew 12x YoY
Q4FY2025 Performance Highlights
- Revenue at ₹11,904m, grew 17.0% YoY
- Gross margin at ₹6,914m, grew 18.1% YoY
- EBITDA grew 22.0% YoY to ₹2,179m with EBITDA margin at 18.3%, grew 75bps YoY
- US revenue at $77m, grew 23.2% YoY
- Operational PAT at ₹1,130m, Grew 5x YoY
- Operational EPS at ₹12.3, Grew 5x YoY
Bangalore, India, May 22, 2025 – Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) today announced its consolidated financial results for the quarter (Q4FY25) and full year (FY25) ended March 31, 2025.
Financial Highlights (In ₹ m)
| Particulars | FY25 | FY24 | YoY | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ | |||||||||
| Revenue | 45,653 | 38,945 | 17.2% | 11,904 | 10,178 | 17.0% | 11,537 | 3.2% | |||||||||
| Gross Margin | 25,854 | 21,455 | 20.5% | 6,914 | 5,855 | 18.1% | 6,735 | 2.7% | |||||||||
| Gross Margin % | 56.6% | 55.1% | 154bps | 58.1% | 57.5% | 56bps | 58.4% | -30bps | |||||||||
| EBITDA | 8,028 | 5,868 | 36.8% | 2,179 | 1,786 | 22.0% | 2,103 | 3.6% | |||||||||
| EBITDA % | 17.6% | 15.1% | 252bps | 18.3% | 17.5% | 75bps | 18.2% | 7bps | |||||||||
| Operational PAT* | 3,447 | 279 | 12x | 1,130 | 242 | 5x | 925 | 22% | |||||||||
| Operational EPS (₹) | 37.5 | 3.1 | 12x | 12.3 | 2.7 | 5x | 10 | 22% |
*Operational PAT = Reported PAT from continuing operations excluding exceptional items
Numbers presented have been adjusted to reflect the impact of the demerged Softgel business to OneSource
Arun Kumar, Founder & Non-Executive Chairperson, and Badree Komandur, MD & Group CEO, commented on the performance and said, “We are pleased to report a strong close to FY25, having successfully exceeded the outlook communicated across all key parameters. Our FY25 revenue grew by 17.2% YoY, outperforming our guidance of 12–15%, aided by strong US business performance. We also surpassed our EBITDA outlook, delivering ₹8,028m in FY25, reflecting enhanced operational efficiency and margin resilience post-demerger. We reduced Net debt by ₹5,128m, and our Net Debt-to-EBITDA ratio improved to 1.9x, well below the outlook given. The US business recorded $291m in revenue, representing 21.8% YoY growth and exceeding the outlook. This was propelled by new product launches, steady base business, and a strong commercial execution framework. We also delivered an operating PAT of ₹3,447m for FY25, reflecting continued focus on profitability. The Board has recommended a dividend of ₹4 per share for FY25, reflecting our strong financial performance.
As we look ahead, we remain focused on the disciplined execution of our business strategies, underpinned by strong governance and a deep commitment to ESG — all aimed at delivering superior business outcomes and creating long-term value for all stakeholders.”
